You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Investigational Drug Information for Vadastuximab Talirine


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Vadastuximab Talirine?

Vadastuximab Talirine is an investigational drug.

There have been 5 clinical trials for Vadastuximab Talirine. The most recent clinical trial was a Phase 1 trial, which was initiated on May 1st 2016.

The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, Acute, and Leukemia, Myeloid. The leading clinical trial sponsors are Seagen Inc., Seattle Genetics, Inc., and [disabled in preview].

There are two US patents protecting this investigational drug and fifty-three international patents.

Recent Clinical Trials for Vadastuximab Talirine
TitleSponsorPhase
Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid LeukemiaSeagen Inc.Phase 3
Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid LeukemiaSeattle Genetics, Inc.Phase 3
Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDSSeagen Inc.Phase 1/Phase 2

See all Vadastuximab Talirine clinical trials

Clinical Trial Summary for Vadastuximab Talirine

Top disease conditions for Vadastuximab Talirine
Top clinical trial sponsors for Vadastuximab Talirine

See all Vadastuximab Talirine clinical trials

US Patents for Vadastuximab Talirine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Vadastuximab talirine ⤷  Try a Trial Syringe plunger assemblies W. L. Gore & Associates, Inc. (Newark, DE) ⤷  Try a Trial
Vadastuximab talirine ⤷  Try a Trial High concentration protein formulations with reduced viscosity Bhami's Research Laboratory, Pvt. Ltd. (Mangalore, IN) ⤷  Try a Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Vadastuximab Talirine

Drugname Country Document Number Estimated Expiration Related US Patent
Vadastuximab talirine Australia AU2017207281 2036-01-11 ⤷  Try a Trial
Vadastuximab talirine Australia AU2017207284 2036-01-11 ⤷  Try a Trial
Vadastuximab talirine Brazil BR112018013663 2036-01-11 ⤷  Try a Trial
Vadastuximab talirine Brazil BR112018013679 2036-01-11 ⤷  Try a Trial
Vadastuximab talirine Canada CA3009194 2036-01-11 ⤷  Try a Trial
Vadastuximab talirine Canada CA3010754 2036-01-11 ⤷  Try a Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.